Opiant Pharmaceuticals (OPNT) announced the expiration of the waiting period under the HSR Act, with respect to the previously announced agreement for Opiant to be acquired by Indivior.
According to a New York Times report, Microsoft’s (MSFT) legal team expects the UK’s Competition and Markets Authority will oppose its planned purchase of Activision (ATVI).
Chiesi Farmaceutici filed with the Austria Federal Competition Authority for its proposed acquisition of Amryt Pharma (AMYT).
Only plus or premium subscribers can access this post. Subscribe today.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
